???????????? ???????????? ????????'?? ?????????? ?????? ??????????????????????????. Traditional market access strategies assume you have years to execute, not months. That's why we don't just deliver strategies, we build ???????????????????????? ????????????????????: step-by-step plans with clear actions, not vague recommendations. Then, we partner with you to implement. Now, you can launch into a market that's primed for your new treatment. ???????????? | ???????????????????????? ???????????????????? ?????? ???????????????????????? ????????????????????. "They cut through the complexity and gave us a clear direction when we needed it most. It shaved months off our accelerated timeline." - ?????? ???????????? ????????????, ???????? ?????????????? ??????????????
Alkemi的外部链接
Alkemi转发了
In 2025, the constraint isn’t budget. It’s attention. And many are spending it poorly - because persuasion is a function of precision, not volume. Attention is the scarce resource. Selectivity is the strategy. How much of your budget is building a case and how much is just building collateral?
Alkemi转发了
When critical dimensions of patient experience go unmeasured, they go unconsidered. In rare disease management, what's overlooked are relevant factors - caregiver experience, productivity impacts, and quality-of-life outcomes - that extend far beyond clinical metrics. Without data on the full burden, decision-makers can't properly allocate resources. The consequences? Inefficiencies, higher costs, and unaddressed patient needs. By capturing holistic patient experience data, we enable smarter decisions that address the true burden of rare diseases. Because bridging?RWE gaps isn't just about better metrics. It's about better lives.
Alkemi转发了
?????? ?????? ?????????????? with the "handoff" model of commercialization? Organizations built to develop treatments - aren't set up to navigate the complex web of stakeholder demands that follow. ???????? ?????????? ???? Medical Affairs generating evidence, HEOR building economic models, and Market Access crafting payer messaging - all working diligently but separately. ???? ?????????????? ???? a cohesive story, decision-makers get fragments that don't address their real decision criteria. ???????? ???????????? ?????????????? ???? ???? map what truly drives decisions - not what stakeholders claim matters, but what actually influences their choices. ???? ????????, market leaders coordinate fragmented teams around what drives stakeholder adoption. The result is the confidence of knowing exactly what each decision-maker needs to hear and having the evidence to back it up. The cost of delay? Millions in revenue and patients still waiting. The assembly line was revolutionary for car manufacturing. For breakthrough treatments, it's revolutionary in the wrong direction.
The Road Less Funded: Why Biotech Innovation is Stuck A conversation between Betsy J. Lahue and biotech innovation expert Cenk Sumen on bridging the gap between clinical innovation and commercial strategy.
Biotech innovation has hit a wall. While R&D budgets grow, true breakthroughs shrink. What we celebrate as "innovation" today would barely qualify as line extensions a decade ago. The costly disconnect? Commercial and clinical teams operate as separate entities: - Different objectives - Different timelines - Different measures of success Leaders are gaining advantage by demolishing these silos and integrating commercial strategy into innovation pipelines from day one. The result? Faster market access, stronger formulary position, and significantly higher ROI on development investments. Thank you Cenk Sumen for this valuable conversation bridging clinical innovation with commercial strategy - a connection companies must make. https://lnkd.in/e_6yu9vv
Alkemi转发了
Strategy sets direction. Execution delivers results. Most teams separate the two.
Alkemi转发了
The biggest barrier to access? The wrong strategy.
HEOR and Market Access teams are under new scrutiny. Restructuring is reshaping Value functions despite their critical role in commercial success. Budgets are tighter. Expectations are higher. The pressure to prove impact is growing. In Value in the Crosshairs, we reveal why Value teams are under scrutiny and how leaders can reshape perceptions, proving they are not cost centers, but critical strategic drivers. Download the proven framework for securing resources and demonstrating commercial impact. Download the report: https://lnkd.in/e7cruRi4 Created in collaboration with experts: Nicholas Backman, Michael Lacey, Debanjali Mitra, Carolina Reyes, John Sears, PhD, MBA, Shuvayu Sen, Ted Slocomb, Samuel Wagner, Neil Warnock, MD, MS, CHCQM, Jennifer Whiteley Alkemi: Betsy J. Lahue, Lake Murphy, Ethan Donnelly
Alkemi转发了
???????????????? ?????????? ???????? ???????????? ????????????????.
Alkemi转发了
I've been contemplating how our industry has drifted away from the initial purpose of strategy. Because a worthwhile strategy doesn't just tell you what to do, it tells you how to think. Interested in your thoughts on this...
Alkemi转发了
If you've ever read a 100-page access strategy deck and learned nothing new... that was the point. Pretty slides, nodding heads, invoices paid and zero real guidance on what to do next. Strategy should be built for markets, not meeting rooms.